PROC earnings

Net Revenues Increased 5% in 9M23 Year-over-Year on a Constant Currency Basis, Driven by 13% RX Growth Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended September 30, 2023 ("3Q23") and the nine months ended September 30, 2023 ("9M23"). Financial Highlights 3Q23 & 9M23 Net revenues totaled $118 million for 3Q23, positively impacted by the performance of RX and OTC portfolios, offset by lower CDMO revenues. On a constant currency basis, net revenues increased by 2% in 3Q23. For 9M23, net revenues totaled $313 million, an incre

Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that it is postponing the previously-announced earnings conference call (currently scheduled for November 16, 2023) to a later date after Procaps publishes its results for the third quarter and nine months ended September 30, 2023 ("3Q23"). Procaps will host a conference call in conjunction with its release of the 3Q23 Results, and call/webcast details will be provided in advance of the call. About Procaps Group Procaps Group, S.A. ("Procaps") (NASDAQ:PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplie

Company to Host Conference Call on Thursday November 16, 2023 at 10:30 a.m. Eastern Time Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced it will report its results for the third quarter and nine months ended September 30, 2023, after market closes on Tuesday, November 14, 2023. The Company will host a conference call and webcast on Thursday, November 16, 2023, at 10:30 a.m. Eastern time, to discuss the third quarter and nine months 2023 results. To access the call, please use the following information: Date: Thursday, November 16, 2023 Time: 10:30 a.m. ET Webcast: Cli

Net Revenues Increased 7% in 1H23 Year-over-Year, on a Constant Currency Basis, Signaling Positive Performance of Rx Products Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended June 30, 2023 ("2Q23") and the six months ended June 30, 2023 ("1H23"). "Amidst a challenging 2Q23, we are accelerating our strategic plan, bolstered by operational agility. While short-term impacts were expected, we believe our proactive approach to cost-cutting positions us for a resilient 4Q23. We are addressing cash flow concerns, adapting pricing str

Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will report its results for the second quarter and six months ended June 30, 2023, before market opens on Tuesday, September 5, 2023. The Company will host a conference call and webcast at 11:00 a.m. Eastern time, on the same day, to discuss the second quarter and first half 2023 results. To access the call, please use the following information: Date: Tuesday, September 5, 2023 Time: 11:00 a.m. ET Webcast: Click here to access Toll Free dial-in number: 1-844-204-8586 Toll/Internationa

Constant Currency Net Revenues Increased 7% Year-over-Year in 2022, With Strong Demand of RX and Softgel Portfolios, Offset by Clinical Specialty Covid Portfolio Preliminary Results for 1Q23 Show a Significant Rebound from 4Q22 Performance, Company Expects to Reach at Least High Single-Digit Growth in Adjusted EBITDA Management Reaffirms Preliminary FY2023 Net Revenue and Adjusted EBITDA Guidance Multiple Value-Creation Initiatives Implemented and On Track to Achieve Up to $15 million of Targeted Recurring Savings Company to Host Conference Call and Webcast Monday, May 15, 2023 at 10:00am Eastern Time Procaps Group S.A. (NASDAQ:PROC) ("Procaps"), a leading integrated international

MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced today that it will file its Form 20-F and publish its Full Year 2022 Earnings Release before May 15th. The delay in filing the 2022 Form 20-F is because additional time is necessary to prepare and complete the internal review of the Company's financial statements for the year ended December 31, 2022. Procaps is making every effort to file its 2022 Form 20-F as soon as practicable. In conjunction with the 20-F filing, Procaps will publish its Full Year 2022 Earnings Release and ho

Reports Preliminary Financial Estimates for Net Revenue and Adjusted EBITDA for Full Year 2022 Realigns Board of Directors to Focus on Profitable Growth Announces $5M+ Share Repurchase Program Commences $15MM Cost Reduction Plan to Improve Margins and Financial Performance 20-F & Conference Call for Q4 and FY 2022 Financial Results Expected to Occur in March 2023 MIAMI and BARRANQUILLA, Colombia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ:PROC) ("Procaps" or the "Company"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today issued a letter to shareholders from Ruben Minski, Chairman of the Board and CEO of Procaps, including preliminary select f

MIAMI and BARRANQUILLA, Colombia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the three months ended September 30, 2022 ("3Q22") and the nine months ended September 30, 2022 ("9M22"). "Demand remains robust for RX and consumer health products as well as for all our CDMO products, and gross margin remained strong despite the challenging macro scenario we have been facing. We have continued to invest and prepare the company for the organic and inorganic growth that is about to come, and we expect to see continued revenue growth and improved ope

MIAMI and BARRANQUILLA, Colombia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it expects to report its results for the third quarter ended September 30, 2022, after the market closes on Monday, November 14, 2022. The Company expects to host a conference call and webcast at 04 p.m. Eastern time, on November 16, 2022.To access the call, please use the following information: Date:Wednesday, November 16, 2022Time:04 p.m. ETToll Free dial-in number:1-844-204-8586Toll/International dial-in number:1-412-317-6346Procaps HD Phone:https://bit.ly/PROCHDPHONEConference ID:Procaps Group

Net Revenues Increased 14% year-over-year in the Second Quarter, with Adjusted EBITDA Margin of 24%Constant currency Net Revenues Increased by 18% year-over-year in the First Half, signaling a strong demand across our businesses MIAMI and BARRANQUILLA, Colombia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the three months ended June 30, 2022 ("2Q22") and the six months ended June 30, 2022 ("1H22"). "The second quarter and first half of 2022 continued our previous year's momentum with healthy demand across most of our business units supported

MIAMI and BARRANQUILLA, Colombia, June 02, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its preliminary financial results for the quarter ended March 31, 2022 ("Q1-22"). Preliminary Q1-22 Results Highlights Net revenues for Q1-22 totaled $86 million, an increase of 11% when compared with the quarter ended March 31, 2021 ("Q1-21"), primarily driven by strong demand across Procaps Colombia, CAN and CASAND, as well as from our continued rollout of new product launches.Adjusted EBITDA increased by 15% to $9 million for Q1-22, with an Adjusted EBITDA margin of 11% for the q

This acquisition reaffirms Procaps Groups' strategy to become one of the fastest growing pharmaceutical organizations in Latin America With FY2021 Net Revenues of $184 million, Grupo Somar is one of the most relevant independent pharma companies in Mexico MIAMI and BARRANQUILLA, Colombia, May 17, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced it has entered into a definitive agreement to acquire Grupo Somar (including Grupo Farmacéutico Somar and Química y Farmacia and, Gelcaps and related entities) from Advent International ("Advent"), one of the world's largest private equity i

Fiscal Year 2021 Net Revenues Increased 23.6% to $409.7 Million, with Adjusted EBITDA Up 17.8% Year-Over-Year to $99.7 Million Strong Double Digit 2021 Revenue Growth in All Business Units Driven by Market Share Gains and New Product Launches Company to Host Business Update Call on Thursday, May 5, 2022, at 10 a.m. Eastern Time Procaps Group S.A. (NASDAQ:PROC) ("Procaps"), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2021. "Our performance in 2021 exceeded our initial projections across all our business units as we achieved record financial milestones with sales brea

Third Quarter 2021 Net Revenues Increased 35% to $106.8 Million Year-Over-Year with Adjusted EBITDA Up 27% Year-Over-Year to $24.5 Million First Nine Months Net Revenues Increased 33% to $283.2 Million, with LTM Net Revenues at $401.4 Million and LTM Adjusted EBITDA up to $100.3 Million Strong Double Digit Revenue Growth in Four Out of Five Business Units Driven by Market Share Gains and New Product Launches Closed Business Combination with Union Acquisition Corp. II on September 29, 2021, and Listed on The Nasdaq Global Market Under "PROC" on September 30, 2021 As a Result of the Business Combination, Procaps Group Ended the Third Quarter 2021 with $100.2 Million in Unrestricted Cash a